Abstract
Background: CD137L, a member of the tumour necrosis factor receptor (TNFR) family, is constitutively expressed on activated antigen-presenting cells. In a wide range of solid tumours, over-expression of CD137L has been shown to produce tumour immunity. This was at least partly due to the stimulation of CD8+ CTL. Costimulation by other known interactions was not unconditionally necessary. Anti-tumour effects were even increased when immunotherapy with Interleukin-12 was additionally employed, either systemically or locally. Yet, there is rare data on the effect of CD137L immunotherapy in hematological malignancies. Here, we present data obtained in a murine plasmocytoma model to evaluate the effect of CD137L and IL-12, either as mono- or combination therapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
